Merck & Co. (MRK)
(Delayed Data from NYSE)
$128.97 USD
+1.67 (1.31%)
Updated Jul 11, 2024 04:00 PM ET
After-Market: $128.96 -0.01 (-0.01%) 7:58 PM ET
2-Buy of 5 2
C Value A Growth C Momentum B VGM
Brokerage Reports
0 items in cart
Merck & Co., Inc. [MRK]
Reports for Purchase
Showing records 341 - 360 ( 396 total )
Company: Merck & Co., Inc.
Industry: Large Cap Pharmaceuticals
Technicals Prescribe Long Positions in Health Care Stocks
Provider: Drexel Hamilton, LLC
Analyst: SINE B
Company: Merck & Co., Inc.
Industry: Large Cap Pharmaceuticals
Company: Merck & Co., Inc.
Industry: Large Cap Pharmaceuticals
Company: Merck & Co., Inc.
Industry: Large Cap Pharmaceuticals
Company: Merck & Co., Inc.
Industry: Large Cap Pharmaceuticals
Company: Merck & Co., Inc.
Industry: Large Cap Pharmaceuticals
Company: Merck & Co., Inc.
Industry: Large Cap Pharmaceuticals
Zacks Earnings Trends: Will Earnings Growth Bottom in Q2? Companies mentioned- FDX, ORCL, PFE, ABT, MRK, DRI, WAG, AAPL
Provider: ZACKS INVESTMENT RESEARCH
Analyst: MIAN S
Company: Merck & Co., Inc.
Industry: Large Cap Pharmaceuticals
Zacks Earning Trends: Q2 Earnings Expectations Remain Low- Companies mentioned: FDX,ORCL,DRI,GS,JPM,PFE,MRK
Provider: ZACKS INVESTMENT RESEARCH
Analyst: MIAN S
Company: Merck & Co., Inc.
Industry: Large Cap Pharmaceuticals
Company: Merck & Co., Inc.
Industry: Large Cap Pharmaceuticals
Company: Merck & Co., Inc.
Industry: Large Cap Pharmaceuticals
Company: Merck & Co., Inc.
Industry: Large Cap Pharmaceuticals
Company: Merck & Co., Inc.
Industry: Large Cap Pharmaceuticals
Company: Merck & Co., Inc.
Industry: Large Cap Pharmaceuticals
Fourth Quarter Revenue Impacted by a Full Quarter of Generic Competition for Singulair
Provider: J.J.B. Hilliard, W.L. Lyons
Analyst: O'NEIL S
Company: Merck & Co., Inc.
Industry: Large Cap Pharmaceuticals
Company: Merck & Co., Inc.
Industry: Large Cap Pharmaceuticals
Third Quarter Reflected the Singulair Patent Expiration
Provider: J.J.B. Hilliard, W.L. Lyons
Analyst: O'NEIL S